<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02848105</url>
  </required_header>
  <id_info>
    <org_study_id>RJH-aGVHD-2016</org_study_id>
    <nct_id>NCT02848105</nct_id>
  </id_info>
  <brief_title>Valproic Acid With Methylprenisonlone for the Treatment of Acute GVHD</brief_title>
  <official_title>Phase II Study of Valproic Acid With Methylprenisonlone for the Treatment of Grade II-IV Acute GVHD in Patients After Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      aGVHD remains as complication in patients after allogeneic stem cell transplantation.
      Methylprednisolone at 1~2mg/kg is considered as standard first-line treatment. In recent lab
      study, we demonstrated that valproic acid (VPA) as histone deacetylase inhibitor can inhibit
      CD4+ Th1 and Th17 cells and control the aGVDH in mice model while preserve the GVL effects.
      In this study, we tested the hypothesis that adding VPA to standard dose steroid treatment
      may improve the outcome of aGVHD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the complete response rate of VPA+Methylpednisolone in patients with Grade II-IV
      aGVHD after allogenetic stem cell transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete response</measure>
    <time_frame>28 days after the treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response (complete + partial response)</measure>
    <time_frame>28 days after the treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Peripheral Blood Stem Cell Transplantation</condition>
  <condition>aGVHD</condition>
  <arm_group>
    <arm_group_label>VPA+Methyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VPA added to standard methylpredisonlone treatment for aGVHD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VPA</intervention_name>
    <description>Valproic acid with 1000mg loading dose with 500mg q12 4 hours later to maintain a trough level above 75ug/ml</description>
    <arm_group_label>VPA+Methyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Grade II-IV aGVHD

          -  No previous history of allergy to valproic acid

          -  No active and severe infection

        Exclusion Criteria:

          -  Inclusion in other clinical trial

          -  GVHD Prophylaxis with valproic acid

          -  severe organ dysfunction: heart, lung, liver and kidney
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiong HU, M.D.,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiong HU, M.D.,</last_name>
    <email>hujiong@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ling Wang, M.D.,</last_name>
    <email>cclingjar@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Blood &amp; Marrow Transplantation Center, RuiJin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiong HU, M.D.,</last_name>
      <phone>86-21-64370045</phone>
      <email>hujiong@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ling Wang, M.D.,</last_name>
      <phone>86-21-64370045</phone>
      <email>cclingjar@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <last_update_submitted>July 29, 2016</last_update_submitted>
  <last_update_submitted_qc>July 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jiong HU</investigator_full_name>
    <investigator_title>Head, Blood and Marrow Transplantation Program</investigator_title>
  </responsible_party>
  <keyword>aGVHD</keyword>
  <keyword>valproic acid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

